| 12/22/2025 | BKEMGNHY | Moody's revises Teva outlook to positive
|
| 12/22/2025 | BKEMGNHY | S&P raises Teva
|
| 6/3/2025 | EMGNHYLM | Teva prices, gives early results of six-series tender offer, ups caps
|
| 6/3/2025 | EMGNHYLM | Teva gives early results of six-series tender offer, ups caps
|
| 5/22/2025 | EMGNHYLM | Teva ups tender cap for six-series offer to $2.25 billion
|
| 5/20/2025 | EMHY | New Issue: Teva Pharmaceutical sells $1.2 billion and €1 billion notes in three tranches
|
| 5/20/2025 | BKEMHY | Fitch raises Teva
|
| 5/20/2025 | EMHY | Teva Pharmaceutical sets talk in $2 billion three-part notes offering; books close Tuesday
|
| 5/19/2025 | BKCVDDEMIGPV | Market Commentary: Calendar balloons, $4.9 billion in the market; Herc active; Avis lower
|
| 5/19/2025 | BKEMGNHY | S&P gives Teva Pharmaceuticals notes BB
|
| 5/19/2025 | EMHY | Teva Pharmaceutical starts roadshow for $2 billion equivalent three-part bullet notes
|
| 5/19/2025 | EMGNHYLM | Teva offers to buy notes from six series for up to $2 billion
|
| 5/15/2025 | BKEMHY | Moody's raises Teva
|
| 11/19/2024 | BKEMHY | S&P raises Teva
|
| 10/10/2024 | BKEMHY | Moody’s raises Teva view to positive
|
| 9/18/2024 | BKEMHY | Fitch raises Teva
|
| 6/24/2024 | BKCVEMHY | S&P turns Teva outlook to positive
|
| 3/7/2024 | BKEMHY | Fitch revises Teva outlook to positive
|
| 5/31/2023 | BKCVEMHY | S&P turns Teva outlook to stable
|
| 3/13/2023 | EMHYLM | Teva gives results, ups caps in offer for $2.5 billion of notes
|
| 3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes
|
| 3/1/2023 | EMGNHY | New Issue: Teva prices upsized $2.49 billion equivalent sustainability notes in four tranches
|
| 3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes
|
| 3/1/2023 | EMGNHY | Teva upsizes to $2.49 billion, hones talk on four-part notes offering; pricing Wednesday
|
| 2/28/2023 | EMGNHY | Moody's assigns Ba2 to Teva notes
|
| 2/28/2023 | EMGNHY | Teva sets talk in $2.06 billion four-part sustainability-linked notes offering; pricing Wednesday
|
| 2/27/2023 | BKCVDDEMIGPV | Market Commentary: Triumph, Teva on deck; Tegna tanks on FCC acquisition opposition; TransDigm, Uniti improve
|
| 2/27/2023 | EMHYLM | Teva starts tender offer for $2.25 billion of notes due 2023 to 2026
|
| 2/27/2023 | EMGNHY | Teva starts roadshow for $2.06 billion four-part offering of sustainability-linked notes
|
| 2/24/2023 | EMHY | Israel’s Teva sets non-deal roadshow via Citigroup and Goldman Sachs in week ahead
|
| 7/29/2022 | BKCVEMGNHY | S&P lifts Teva outlook to positive
|
| 7/27/2022 | BKCVDDEMIGPV | Market Commentary: Avient prices; secondary surges post-Fed; cross-over credits in demand; Teva gains on settlement
|
| 12/15/2021 | BKCVEMGNHY | Moody's turns Teva outlook to stable
|
| 12/6/2021 | BKCVEMGNHY | Fitch revises Teva view to stable
|
| 11/10/2021 | EMHYLM | Teva gives early tender results for six series, lifts cap to $4 billion
|
| 11/5/2021 | EM | Market Commentary: Emerging markets: Teva prices upsized $5 billion equivalent notes: NPC Ukrenergo debuts
|
| 11/4/2021 | BKCVDDEMIGPV | Market Commentary: DCP Midstream, Asbury Automotive price; Teva active; Continental gains; CommScope sinks
|
| 11/3/2021 | BKCVDDEMIGPV | Market Commentary: Junk secondary unmoved by Fed tapering statement; Teva flat; Jane Street on a 101-handle
|
| 11/2/2021 | EMGNHY | New Issue: Teva Pharmaceutical prices upsized $5 billion equivalent sustainability-linked notes
|
| 11/1/2021 | BKCVDDEMIGPV | Market Commentary: Mr. Cooper, Navient price; loanDepot gains on earnings beat; PG&E active
|
| 11/1/2021 | EMGNHY | Teva sets price talk in $4 billion equivalent four-part sustainability notes offer, pricing Tuesday
|
| 10/29/2021 | EM | Market Commentary: Emerging Markets: Peru brings sustainable bonds; Teva on tap; Modern Land skips payment
|
| 10/27/2021 | EMGNHY | Junk investors dig in on Teva’s $4 billion four-part offering of sustainability-linked notes
|
| 10/27/2021 | EMHYLM | Teva Pharmaceutical commences capped cash tender offer for six series of notes
|
| 10/27/2021 | EMHY | S&P assigns Teva notes BB-
|
| 10/27/2021 | EMHYLM | Teva Pharmaceutical begins cash tender offer for six series of notes
|
| 10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes; pricing expected Tuesday
|
| 10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes
|
| 10/27/2021 | EMHY | Moody's rates Teva notes Ba2
|
| 9/3/2020 | BKCVEMHY | S&P trims Teva
|
| 11/25/2019 | DDEMHYLM | Teva gives early results for tenders for 2.2%, 3.65% notes due 2021
|
| 11/21/2019 | EMHYLM | Teva Pharmaceutical to redeem €650 million of 3/8% notes
|
| 11/19/2019 | EMHY | New Issue: Teva Pharmaceutical prices $1 billion 7 1/8% notes and €1 billion 6% notes at par
|
| 11/19/2019 | EMHY | Teva Pharmaceutical upsizes bond tranches, tightens talk amid huge demand; pricing Tuesday
|
| 11/19/2019 | EMHY | Teva Pharmaceutical ups bond tranches to $1 billion and €1 billion, tightens talk; pricing Tuesday
|
| 11/18/2019 | BKCVDDEMIGPV | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands trades up
|
| 11/18/2019 | EMHY | Teva sets tranches, talk for upsized $2 billion equivalent long five-year dual-currency notes
|
| 11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2
|
| 11/13/2019 | BKCVEM | S&P rates Teva notes BB
|
| 11/13/2019 | EMHY | Teva Pharmaceutical sets initial price talk in $1.5 billion dollar, euro notes offering
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
| 11/8/2019 | DDEMHYLM | Teva tenders for 2.2%, 3.65% notes, will spend up to $1.5 billion
|
| 11/8/2019 | EMHY | Teva Pharmaceutical sets roadshow for $1.5 billion two-part bullet deal in dollars and euros
|
| 10/24/2019 | BKCVEM | S&P places Teva ratings on CreditWatch negative
|
| 10/21/2019 | BKCVDDEMIGPV | Market Commentary: United Rentals, KB Home price; newer notes trade; Teva lifted; Coty falls; WeWork higher
|
| 10/18/2019 | BKCVDDEMIGPV | Market Commentary: Neptune Energy adds; Evoca prices; Thursday issuance higher; Teva up; WeWork better
|
| 10/16/2019 | BKCVDDEMIGPV | Market Commentary: Merlin, Speedway price; new Charter notes rise; pharma names up; Sprint, T-Mobile higher
|
| 8/28/2019 | BKCVDDEMIGPV | Market Commentary: Pharma space under pressure; Rackspace higher; Tallgrass negative; oil names rise
|
| 8/27/2019 | BKCVDDEMIGPV | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
| 8/14/2019 | BKCVEM | Moody’s revises Teva view to negative
|
| 8/13/2019 | BKCVDDEMIGPV | Market Commentary: Post Labor Day pipeline eyed; Tenet bounces off lows; Teva drops; Goodyear Tire rises
|
| 7/23/2019 | BKCVDDEMIGPV | Market Commentary: JBS USA, Five Point add-on price; Teva in focus; LSC Communications craters
|
| 7/5/2019 | BKCVDDEMIGPV | Market Commentary: Trading light; Altice USA backs off gains; Teva active but flat; funds add $800 million
|
| 6/7/2019 | BKCVEM | Fitch downgrades Teva
|
| 6/3/2019 | BKCVDDEMIGPV | Market Commentary: Multi-Color, Grubhub on tap; Neiman Marcus, GCI price; Teva in focus, gains; Altice up
|
| 5/29/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial prices; Frontier gains; Teva’s downward spiral continues; CRC drops
|
| 5/28/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial, GoDaddy on tap; Fiat up on merger; Teva drops post settlement
|
| 5/15/2019 | BKCVDDEMIGPV | Market Commentary: Transocean prices; Berry on tap; VistaJet active; Teva, Commscope under pressure
|
| 5/13/2019 | BKCVDDEMIGPV | Market Commentary: Eldorado on tap; Bausch Health weakens; Charter below par; Weatherford, Teva down
|
| 2/15/2019 | BKCVEM | S&P revises Teva view to negative
|
| 2/14/2019 | BKCVEM | S&P lowers Teva view to negative
|
| 1/4/2019 | BKCVDDEMIGPV | Market Commentary: Risk-on sentiment returns; CDX sees largest single-day gain in four years; energy outperforms
|
| 1/3/2019 | BKCVDDEMIGPV | Market Commentary: No new deals in sight; trading volume light; Western Digital active; Qorvo drops; Teva up
|
| 11/1/2018 | BKBWCVEMHY | Israel’s Teva is using majority of cash flow to reduce leverage to 3x
|
| 10/11/2018 | BKCVDDEMIGPV | Market Commentary: Millicom prices; TransDigm rises on acquisition; energy mixed; Teva Pharaceutical improves
|
| 9/18/2018 | EMHYLM | Israel’s Teva to buy some 1.7%, 3/8% notes in oversubscribed tender
|
| 9/14/2018 | BWEMHY | Teva sees slump in profits, rise in debt due to Copaxone competition
|
| 9/4/2018 | EMHYLM | Israel’s Teva to pay up to $400 million in tenders for three issues
|
| 8/15/2018 | BKCVEM | Fitch affirms Teva Pharmaceutical
|
| 7/27/2018 | BKCVDDEMIGPV | Market Commentary: Hi-Crush prices, euro primary active; Party City’s new issue lower; Teva slides
|
| 7/26/2018 | BKCVDDEMIGPV | Market Commentary: Party City prices; Teva improves; Aleris acquired; SuperValu bought; funds off $548 million
|
| 7/20/2018 | BKCVDDEMIGPV | Market Commentary: Comstock prices; Bruin carried over; secondary trading light; IHS Markit eyed; Teva active
|
| 3/16/2018 | BKCVDDEMIGPV | Market Commentary: Tullow, Husky lead busy primary; Mattel trades on Toys shutdown; Teva still trades under par
|
| 3/13/2018 | BWEMHY | Teva’s upsized bond sale goes ‘very well’; pricing on low end of talk
|
| 3/7/2018 | BKCVDDEMIGPV | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up
|
| 3/7/2018 | EMHY | New Issue: Teva Pharmaceutical sells upsized $4.5 billion equivalent notes in four tranches
|
| 3/7/2018 | EMHY | Israel’s Teva launches upsized $4.5 billion four-part bond deal; pricing expected Wednesday
|
| 3/6/2018 | BKCVDDEMIGPV | Market Commentary: Three-part CIT drive-by leads deal parade; Ball, William Lyons, Buena Vista also price
|
| 3/6/2018 | EM | Market Commentary: Senegal, KDB price notes; Sharjah prices $1 billion sukuk; Union National brings notes
|
| 3/6/2018 | EMHY | Teva Pharmaceutical sets price talk in $3.5 billion four-part deal; books close Wednesday
|
| 2/28/2018 | BKCVEM | S&P rates Teva notes BB
|
| 2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes
|
| 2/28/2018 | EMHY | Teva Pharmaceutical sets roadshow for $3.5 billion equivalent four-part bullet notes
|
| 1/12/2018 | BKCVEM | Moody’s downgrades Teva to Ba2
|
| 12/14/2017 | BKCVEMIG | Moody’s reviews Teva Pharmaceutical
|
| 11/6/2017 | BKCVEMIG | Fitch downgrades Teva to BB
|
| 11/3/2017 | BKCVEMIG | S&P revises Teva to negative
|
| 9/20/2017 | BKCVEMIG | S&P downgrades Teva
|
| 8/4/2017 | EM | S&P downgrades Congo
|
| 8/4/2017 | BKCVEMIG | Moody's downgrades Teva
|
| 2/3/2017 | BKCVEMIG | S&P: Teva Pharmaceutical outlook to negative
|
| 8/2/2016 | BKCVEMIG | Moody’s downgrades Teva to Baa2
|
| 7/22/2016 | BKCVEMIG | Fitch rates Teva bonds BBB
|
| 7/21/2016 | EM | New Issue: Israel’s Teva Pharmaceutical sells CHF 1 billion notes in three parts
|
| 7/20/2016 | EMHYMUPFPV | Market Commentary: Primary action thins; Citi subordinated notes mixed; Teva stronger; credit spreads firm
|
| 7/20/2016 | EM | New Issue: Israel’s Teva Pharmaceutical Finance prices €4 billion of notes in three tranches
|
| 7/20/2016 | BKCVEMIG | Fitch downgrades Teva, rates bond BBB
|
| 7/19/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
| 7/18/2016 | EMHYMUPFPV | Market Commentary: Teva prices $15 billion; Citi, Wells Fargo tap market; bonds mixed; credit spreads improve
|
| 7/18/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
| 7/18/2016 | BKCVEMIG | S&P rates Teva notes BBB
|
| 7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
| 7/18/2016 | EMIG | Teva Pharmaceuticals in the market with fixed-, floating-rate notes
|
| 7/13/2016 | EMHYMUPFPV | Market Commentary: Japan Bank, Bank of Montreal, International Finance in primary; Anheuser-Busch flat on day
|
| 7/13/2016 | EMIG | Teva sets investor call dates ahead of more than $20 billion equivalent of debt offerings
|
| 7/13/2016 | BKBWEMIG | Teva planned net debt funding for Allergan purchase down by $4 billion
|
| 7/13/2016 | BKCVEMIG | S&P downgrades Teva
|
| 7/13/2016 | EMIG | Teva expected to tap markets for more than $20 billion of debt to fund acquisition
|
| 11/25/2015 | BKCVEMIG | S&P rates Teva loan BBB+
|
| 8/3/2015 | BKEMIG | Israel’s Teva details commitments for $33.75 billion in facilities
|
| 7/31/2015 | BKEMIG | Israel’s Teva gets financing commitments for up to $33.75 billion
|
| 7/28/2015 | BKCVEMIG | S&P lowers Teva Pharmaceutical
|
| 7/27/2015 | BKBWEMIGLM | Teva Pharmaceuticals to obtain up to $27 billion of debt to buy Allergan’s generics business
|
| 7/27/2015 | BKCVEMIG | Moody’s cuts Teva Pharmaceutical to Baa1
|
| 4/22/2015 | BKCVEMIG | Fitch: Teva on watch after merger news
|
| 4/22/2015 | BKCVEMIG | S&P: Teva on watch after Mylan deal announced
|
| 4/21/2015 | BKCVEMIG | Moody's changes Teva outlook to negative
|
| 3/31/2015 | BKCVEMIG | Moody's: Teva unchanged
|
| 3/24/2015 | EM | Market Commentary: New deal from Teva Pharmaceuticals; risk aversion grows; Asia mixed, Lat-Am weakens
|
| 3/24/2015 | EM | New Issue: Israel’s Teva Pharmaceutical sells €2 billion notes due in 2023, 2027
|
| 3/24/2015 | BKCVEMIG | Moody's rates Teva notes A3
|
| 3/24/2015 | BKCVEMIG | S&P rates Teva notes A-
|
| 3/24/2015 | BKCVEMIG | Fitch assigns BBB+ to Teva bond
|
| 3/24/2015 | EM | Israel’s Teva Pharmaceutical mandates four bookrunners for euro notes
|
| 3/11/2015 | EM | Market Commentary: Petronas, Panama, Millicom sell notes; Russia, Turkey, Asia weaken; Braskem tied to scandal
|
| 3/11/2015 | EM | Israel’s Teva Pharmaceutical to issue euro-denominated notes
|
| 2/27/2015 | EMIGLM | Israel’s Teva ups tender purchase amount to $1.3 billion; pricing set
|
| 2/19/2015 | BKCVEMIG | Moody’s revises Teva to stable
|
| 2/12/2015 | EMIGLM | Teva Pharmaceutical tenders for up to $1 billion of four note series
|
| 12/11/2013 | BKCVEM | Fitch downgrades Teva
|
| 6/13/2013 | BKCVEM | Moody's: Teva view to negative
|
| 3/1/2013 | EMIGLM | Israel's Teva Pharmaceutical calls $500 million 5.55% notes due 2016
|
| 12/18/2012 | EM | Teva Pharmaceutical Finance to redeem $1 billion senior notes due 2014
|
| 12/13/2012 | EM | Israel's Teva Pharmaceutical units selling benchmark senior notes due 2020, 2022 on Thursday
|
| 12/13/2012 | EM | New Issue: Teva units price $2 billion of senior notes due 2020, 2022
|
| 12/13/2012 | BKCVEM | Fitch rates Teva notes A-
|
| 12/13/2012 | CVEM | Moody's rates Teva notes A3
|
| 12/13/2012 | CVEM | S&P rates Teva notes A-
|
| 4/3/2012 | CVEMIG | S&P rates Teva notes A-
|
| 4/2/2012 | CVEMIG | Moody's rates Teva notes A3
|
| 3/30/2012 | EM | New Issue: Israel's Teva prices €1 billion 2 7/8% seven-year notes at 100 bps over mid-swaps
|
| 3/29/2012 | CVEMIG | S&P rates Teva notes A-
|
| 3/23/2012 | EM | Israel's Teva plans euro- and Swiss franc-denominated senior notes
|
| 3/23/2012 | EM | Market Commentary: Emerging markets quiet; funds see $851 million of inflows; China Development prices add-on
|
| 12/21/2011 | CVEMIG | Moody's: Teva unchanged
|
| 12/21/2011 | CVEMIG | Teva to end 2011 with $14.5 billion of debt, expects decrease in 2012
|
| 12/9/2011 | CVEMIG | Teva files automatic shelf registration for ADS, debt, units, warrants
|
| 12/6/2011 | BKCVEMIG | Teva has 'robust' rating, 'significant' cash flow for deleveraging
|
| 11/8/2011 | EMIG | New Issue: Teva Pharmaceutical sells $5 billion of senior notes in six tranches
|
| 11/7/2011 | EMIG | Israel's Teva Pharmaceutical to sell $4 billion of senior notes
|
| 11/7/2011 | CVEMIG | S&P assigns Teva notes A-
|
| 8/2/2011 | CVEMIG | Moody's: Teva unchanged
|
| 5/2/2011 | CVEMIG | S&P affirms Teva
|
| 5/2/2011 | CVEMIG | Moody's affirms Teva
|
| 5/2/2011 | CVEMIG | Teva plans to use cash, bonds to acquire Cephalon for $6.8 billion
|
| 3/16/2011 | CVEMIG | S&P rates Teva notes A-
|
| 3/16/2011 | CVEMIG | Moody's rates Teva notes A3
|
| 3/16/2011 | EMIG | New Issue: Teva Pharmaceuticals prices $750 million of senior notes in two tranches
|
| 6/15/2010 | EMIG | New Issue: Teva Pharmaceutical prices $2.5 billion of senior notes in three tranches
|
| 3/19/2010 | CVEMIG | S&P ups Teva Pharmaceutical
|
| 3/18/2010 | CVEMIG | Moody's affirms Teva Pharmaceuticals
|
| 1/13/2010 | CVEMIG | Moody's lifts Teva
|
| 10/14/2009 | CVEMIG | Moody's upgrades Teva
|
| 5/18/2009 | CVEM | Moody's lifts Teva Pharmaceuticals outlook to positive
|
| 1/6/2009 | CVEMIG | Moody's affirms Teva, ups Barr loan
|
| 12/4/2008 | CVEMIG | Teva files automatic shelf registration
|
| 7/18/2008 | BKCVEMIG | Moody's may upgrade Barr, affirms Teva
|
| 7/18/2008 | EMIG | Teva acquires Barr, plans tapping of long-term debt market
|
| 11/7/2006 | BTCVEM | Teva board OKs repurchase of up to $600 million convertibles, shares
|
| 1/27/2006 | BTCVEM | Moody's rates Teva Pharmaceutical notes, convertibles Baa2
|
| 1/27/2006 | BTEM | New Issue: Israel's Teva Pharmaceutical sells $1.5 billion in 2016 and 2036 notes
|
| 1/27/2006 | BTCVEM | New Issue: Teva prices $1.25 billion convertibles at 1.75%, up 25%, 0.25%, up 15%
|
| 1/26/2006 | BTEM | Price talk emerges on Teva $1.5 billion two-tranche straight debt, $1.25 billion of convertibles
|
| 1/26/2006 | BTCVEM | S&P assigns Teva Pharmaceutical notes BBB
|
| 1/25/2006 | BTEM | Teva launches $2.75 billion of bonds to repay bridge financing for Ivax merger
|
| 12/20/2005 | BTCVEM | Teva files shelf, may use sales to finance IVAX acquisition
|
| 11/28/2005 | BTEM | Teva Pharmaceuticals draws down $350 million U.S. loan
|
| 11/14/2005 | EM | S&P affirms Teva Pharmaceutical
|
| 11/2/2005 | BTCVEM | Moody's gives Teva Baa2 issuer rating
|
| 7/25/2005 | BTCVEM | S&P puts Teva on negative watch
|
